Ebola’s Grim Reminder

Insights

Ebola’s Grim Reminder

March 18, 2015

Last summer, I watched with the same horror many felt as reports from West Africa emerged of Ebola’s deadly toll. The virus has devastated families, wreaked havoc on health systems and savaged economies.

But to be frank, I’m much more worried that next time – and there will be a next time – it will be far worse.

Today, Bill Gates makes the case at both TED and in the New England Journal of Medicine that if Ebola has taught us anything, it is how dangerously unprepared we are to deal with a global epidemic. As he so aptly describes the world’s response to Ebola in the New York Times, “The problem isn’t so much that the system didn’t work well enough. The problem is that we hardly have a system at all.”

In an essay I published in 2013 in Lawfare, I raised similar questions about our national security – but in the context of a strategic biological attack. Many of the preventative measures we could take to improve our institutional and infrastructural defenses against bioterrorism are the same ones that would save lives in the event of a pandemic or an emergent pathogen. Antiviral drug research and development, monitoring systems for detecting outbreaks early or coordinated emergency response protocols to name but a few.

Because the next time it might not be Ebola. It might be a new disease like SARS or MERS. Or it might be a strain of flu like the 1918 Spanish Influenza Pandemic. Instead of thousands of deaths, millions, or even hundreds of millions of lives could hang in the balance.

This helps explains in part why Intellectual Ventures has been hard at work on a number of outbreak- related projects over the last six months. Small measures to be certain, but ones I am proud to see contribute to the scientific research whole:

  • The Institute for Disease Modelling (IDM) supported the Ebola response with data-driven analysis of the sub-national patterns of the virus’ spread in West Africa. By illustrating at a district-level were Ebola was increasing, decreasing, and plateauing over time, the data IDM shared with global health partners assisted in planning Ebola responses by the areas that would face an increased burden in the weeks ahead.     
  • Global Good has deployed an ice vest that has helped Ebola health workers spend more time with their patients, with less risk of infection to themselves. We built up this expertise by evaluating hundreds of personal cooling solutions ourselves, and working directly with medical experts to understand what would work best for healthcare workers within the constraints of the Ebola Treatment Centers in West Africa. Since October 2014, IV has deployed over 1,000 personal cooling systems (enough to supply the priority locations) at Ebola Treatment Centers and hospitals in Guinea, Sierra Leone, and Liberia, where the need and case counts were the highest.
  • Global Good is supporting clinical trials led by the World Health Organization and the U.S. Centers for Disease Control and Prevention in Ebola-affected countries, with a modified version of our passive vaccine storage device, called the Arktek. Maintaining the “cold chain” at extremely low temperatures is essential to keeping vaccines safe and effective, especially in areas without reliable electricity supply. 

I do not profess to be an expert in defense, let alone global health. But I will happily be accused of being a technological optimist. I share with Bill an unwavering belief in human ingenuity. I believe we will invent our way out of these problems, as we have done in so many cases before.

But that’s also why we should so listen closely to Bill’s call to action: we need a global warning and response system for outbreaks.

Because Ebola is a tragedy, but it could very well have been a catastrophe. 

More Buzz From IV

Bloomberg Businessweek’s “Hello World” Meets Nathan Myhrvold

Nathan Myhrvold is the subject of the latest "Hello World" episode.

Read More
Advancing Diversity, Equity, and Inclusion at IV

Learn more about DEI at IV.

Read More
IV Announces New Licensing Agreement to its Invention Investment Fund Portfolio

IIF off to a strong start in 2023.

Read More
We use cookies on this website to enhance your browser experience and to analyze your traffic. To learn more about cookies and how we use them view our cookie policy. By continuing to use our website you consent to the use of cookies.